Telix Pharmaceuticals (TLX) investor relations material

Financial performance and guidance

• Achieved over $800 million in sales, driven by U.S. prostate cancer imaging franchise with two FDA-approved products.

• Issued 2026 revenue guidance of $950–$970 million, reflecting strong growth in prostate cancer imaging and new product launches.

• Precision Medicine business unit expected to grow approximately 25%.

Commercial and market expansion drivers

• Growth in PSMA imaging expected at 5–7% annually, with increasing adoption by urologists.

• Launch of a second prostate cancer product with pass-through status is boosting commercial momentum.

• BiPASS phase III trial aims to expand the total addressable market for prostate cancer imaging.

Clinical pipeline and trial updates

• BiPASS trial could enable 750,000–800,000 additional scans annually in the U.S., improving diagnostic accuracy and patient compliance.

• ProstACT Global phase III trial in mCRPC demonstrated favorable safety and dosimetry, with manageable hematologic toxicities.

• Part 2 of ProstACT Global is enrolling globally, with U.S. participation expected to increase mid-year.

• IPAX BrIGHT phase III trial in recurrent glioblastoma is underway, focusing on layering radioligand therapy with standard of care.

• TLX250 program in renal cell carcinoma is targeting last-line patients, with companion imaging agent Zircaix expected to launch this year.